MedRelay

The description states that MedRelay is an AI-powered handoff assistant for medical consultations. It guides users through a conversation-driven symptom intake process, using text and voice inputs to generate structured summaries for clinicians.

• It can understand symptoms communicated via text and voice.
• It asks follow-up questions.
• It identifies urgent information requiring attention.
• It communicates uncertainty instead of guessing.
• It generates structured handoff summaries.
• It suggests the right type of specialist.
• It helps with doctor discovery and appointment booking.
• It provides dashboards for both patients and clinicians.

The model does not provide diagnosis or treatment; its role is to enhance communication before professional care.

Evidence All of this is self-reported by the author. No external validation, revenue data, or customer feedback are provided.

The author positions MedRelay as an AI-powered assistant for patient-to-clinician handoffs, not a diagnostic tool.

Key claims:

• It helps close communication gaps between patients and doctors.
• It does not pretend to diagnose.
• It enhances preparation before professional care.
• It supports structured, safe, and clear communication.

The project evolved from a prototype in Manus to an application built with GPT-5.6 and Codex during OpenAI Build Week.

Evidence These are claims made by the author; no third-party confirmation or traction data is available.

The description states that MedRelay targets patients who struggle to communicate symptoms clearly, especially those who forget details, provide disorderly descriptions, or find it difficult to articulate what happened and when.

It also implies a secondary audience: clinicians who receive structured summaries from patients.

There is no explicit mention of specific demographics, age groups, or healthcare settings (e.g., primary care, emergency, telehealth).

Evidence Only self-reported customer positioning. No evidence of actual users, market segmentation, or buyer personas.

Not evidenced.

The description does not state anything about:

• How the product will be monetized.
• Whether it is free, subscription-based, or sold to institutions.
• Pricing models or revenue streams.
• Any partnerships or distribution channels.

Evidence No business model or pricing information provided.

MedRelay uses:

• Frontend: React, TypeScript, Three.js, Tailwind CSS
• Backend: Node.js, Express, tRPC, Drizzle ORM
• AI/ML Tools: GPT-5.6, Codex, Structured Outputs
• Features: Voice-enabled input, multi-turn conversation, uncertainty handling, clinician review states

The system is described as having:

• Schema-controlled responses.
• Predictable fields for rendering in dashboards.
• Safety boundaries and failover handling.

It was rebuilt from an existing Manus prototype using Codex to migrate and extend functionality.

Evidence Self-reported technical stack and architecture. No evidence of production deployment, scalability, or performance metrics.

Not evidenced.

The description does not include:

• Number of users.
• Customer adoption or retention data.
• Revenue figures.
• Product usage statistics.
• Clinical trials or user feedback from real-world testing.

It is described as a prototype that was extended during a hackathon and has no mention of ongoing development or deployment beyond the project submission.

Evidence No traction or maturity indicators are provided.

Not evidenced.

The description does not:

• Identify competitors.
• Describe market size or competitive landscape.
• Mention how MedRelay differentiates from existing tools in symptom intake or clinical handoffs.

Evidence No competitive analysis or positioning relative to other tools is included.

Inferences based on self-reported information:

1. Lack of clinical validation: The tool is described as a prototype built during a hackathon, with no evidence of real-world testing or clinical evaluation.
2. Unclear safety and regulatory compliance: No mention of HIPAA, FDA, or other healthcare regulations.
3. No monetization strategy: No indication of how the product will be sold or funded.
4. Unproven user adoption: The project is not described as having users or being used in practice.
5. Dependency on AI model quality: Reliance on GPT-5.6 and Codex without evidence of robustness or error handling.

Evidence All of these are inferred from the lack of real-world data, clinical validation, or business details.

1. Has MedRelay been tested with actual patients or clinicians?
2. What is the plan for integrating with existing healthcare systems or EHRs?
3. How does the tool handle edge cases or ambiguous inputs?
4. Are there any safety or compliance measures in place (e.g., HIPAA, data privacy)?
5. Is there a roadmap for monetization or scaling beyond the prototype stage?
6. What kind of feedback have you received from healthcare professionals?
7. How is uncertainty communicated to users and clinicians?
8. What are the limitations of GPT-5.6 in this context, and how are they mitigated?